Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
Rhea-AI Summary
Tevogen Bio Holdings (Nasdaq: TVGN) reported significant growth in institutional ownership during Q2 2025. The company saw a 24% increase in institutional ownership compared to Q1 2025, following a 60% increase in the previous quarter.
Notable developments include Morgan Stanley and BlackRock increasing their combined holdings by 80%. The number of institutional holders grew from 51 to 55, with 72% of holders either increasing or maintaining their positions. The company attributes this growth to its scientific and operational progress, including positive clinical data and advancement toward internal GMP cell manufacturing capabilities.
Positive
- Institutional ownership increased by 24% in Q2 2025
- Morgan Stanley and BlackRock increased combined holdings by 80%
- Number of institutional holders grew from 51 to 55
- 72% of institutional holders increased or maintained their positions
- Company is advancing toward internal GMP cell manufacturing capabilities
Negative
- Company needs to raise additional capital to execute business plan
- Faces risks in maintaining effective internal controls
- Limited operating history presents operational risks
- Potential challenges in keeping pace with rapid technological developments
News Market Reaction
On the day this news was published, TVGNW declined 3.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
As reported on June 30, 2025, second quarter institutional ownership of Tevogen common stock increased
“The continued increase in ownership by institutional managers is a positive sign and may reflect how Tevogen’s scientific and operational progress is resonating with long-term investors,” said Tapan Shah, Tevogen’s Head of Investor Relations. “We believe the Company’s milestones, from publishing positive clinical data to advancing toward internal GMP cell manufacturing capabilities, could further strengthen institutional confidence in our ability to execute on our mission.”
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What was Tevogen's (TVGN) institutional ownership growth in Q2 2025?
How many institutional holders does Tevogen (TVGN) have as of Q2 2025?
Which major institutions increased their holdings in Tevogen (TVGN)?
What operational developments is Tevogen (TVGN) pursuing?
What are the main risks facing Tevogen (TVGN)?
